This refresher course will provide an overview of the treatment of prostate cancer with an emphasis on the role of radiation therapy in the treatment of localized disease, nodal disease, recurrent disease after prostatectomy, and treatment of the primary in the setting of oligometastatic disease. It will include discussion of optimal systemic therapy to administer with radiation treatment, incorporating predictive biomarkers into practice, normal tissue constraints, and comparative outcomes between radiation, surgery, and active surveillance.
The activity is designed to meet the interests of radiation oncologists and radiation oncology residents.
Upon completion of this activity, participants should be able to do the following:
- Recognize which patients may benefit from microboost, brachytherapy boost, and nodal treatment as part of their definitive prostate radiation treatment.
- Identify the optimal systemic therapy to deliver with salvage radiation treatment.
- Describe the data supporting the treatment of the prostate with radiation therapy in the setting of metastatic disease.
Karen E. Hoffman, MD, MHSc, MOPH, FASTRO is employed by the University of Texas MD Anderson Cancer Center and has received research/grant funding from Janssen and Varian Medical Systems.
All relevant financial relationships have been mitigated.
The person(s) above served as the developer(s) of this activity. Additionally, the Annual Refresher Course Planning Committee had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.75 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.75 Certificate of AttendanceThis activity was designated for 1.75 AMA PRA Category 1 Credit™.